Company intelligence / Profile preview
Krka
- Ownership
- Public · KRKG
- Employees
- ~12753
- Development stage
- Commercial
Overview
Krka is one of the world’s leading generic pharmaceutical companies with over a thousand marketed products across more than seventy countries. Its portfolio includes numerous approved small molecule drugs for cardiovascular disease, diabetes, CNS disorders, oncology and more. The company is known for innovative fixed-dose combinations in hypertension and lipid management as well as expanding into new areas such as novel oral anticoagulants.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularNephrologyEndocrinologyHematologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculeSynthetic peptideDegradable molecular glue therapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Financials
- Market cap
- $45.3B
- Total revenue
- $147.1B
- Enterprise value
- $68.3B
Beyond the preview
Go deeper on Krka.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Krka.